| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.97▲ | 1.98▲ | 1.98▲ | 2.02▼ | 2.04▼ |
| MA10 | 2.00▲ | 2.05▼ | 2.05▼ | 2.06▼ | 2.18▼ |
| MA20 | 2.05▼ | 2.06▼ | 2.05▼ | 2.01▼ | 2.42▼ |
| MA50 | 2.03▼ | 2.02▼ | 2.06▼ | 2.18▼ | 3.32▼ |
| MA100 | 2.04▼ | 2.15▼ | 2.19▼ | 2.47▼ | 6.33▼ |
| MA200 | 2.18▼ | 2.23▼ | 2.25▼ | 3.18▼ | 10.90▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.013▼ | -0.015▼ | -0.011▼ | 0.000▲ | 0.055▲ |
| RSI | 46.188▼ | 45.455▼ | 45.711▼ | 40.019▼ | 35.849▼ |
| STOCH | 19.949▼ | 15.262▼ | 16.954▼ | 42.895 | 39.610 |
| WILL %R | -67.347 | -67.347 | -67.347 | -82.051▼ | -73.770 |
| CCI | -40.476 | -62.877 | -54.895 | -127.817▼ | -98.430 |
| CDL | $SNGX Hammer Candlestick Pattern Detected | Set Alert |
|
Thursday, May 01, 2025 11:39 AM
The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030.
|
|
Tuesday, April 29, 2025 11:53 AM
Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel pho ...
|
|
Friday, April 25, 2025 12:07 PM
Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical pr ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 1.96 | 2.002 | 1.92 | 1.92 | 33,395 |
| 30/04/25 | 1.995 | 1.995 | 1.90 | 1.97 | 7,824 |
| 29/04/25 | 2.04 | 2.10 | 1.98 | 1.98 | 55,088 |
| 28/04/25 | 2.24 | 2.24 | 2.015 | 2.07 | 41,132 |
| 25/04/25 | 2.19 | 2.19 | 2.08 | 2.17 | 19,576 |
| 24/04/25 | 2.04 | 2.21 | 2.04 | 2.155 | 57,874 |
| 23/04/25 | 2.08 | 2.10 | 2.0297 | 2.07 | 21,918 |
| 22/04/25 | 2.055 | 2.09 | 2.0217 | 2.065 | 11,113 |
| 21/04/25 | 2.09 | 2.0918 | 1.97 | 2.07 | 52,991 |
| 17/04/25 | 2.11 | 2.11 | 2.00 | 2.10 | 30,763 |
|
|
||||
|
|
||||
|
|